中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

基于TCGA数据库分析CCDC34基因在肝细胞癌中的表达及意义

向晓辉 毛骏 李海

引用本文:
Citation:

基于TCGA数据库分析CCDC34基因在肝细胞癌中的表达及意义

DOI: 10.3969/j.issn.1001-5256.2020.05.020
基金项目: 

天津市自然科学基金项目(17JCYBJC26700); 

详细信息
  • 中图分类号: R735.7;TP311.13

Expression and clinical significance of CCDC34 in hepatocellular carcinoma:An analysis based on The Cancer Genome Atlas database

Research funding: 

 

  • 摘要:

    目的研究卷曲螺旋结构域蛋白34(CCDC34)基因在肝细胞癌中的表达以及临床价值,预测CCDC34基因在肝细胞癌发生发展中的作用。方法从癌症基因组图谱(TCGA)下载肝细胞癌数据集,获得CCDC34基因表达谱和临床信息。利用生物信息学方法,分析CCDC34基因在肝细胞癌中的表达水平与临床病理指标的相关性以及对预后的影响。用基因集富集分析(GSEA)预测CCDC34基因在肝细胞癌中调控的可能通路。计量资料2组间比较分别采用独立样本t检验及配对t检验。生存分析采用Kaplan-Meier法及log-rank检验;并运用Cox比例风险回归模型分析影响患者预后的危险因素。GSEA判断显著性富集的标准为P<0. 01,且错误发现率(FDR)<0. 05。结果在TCGA数据库中,CCDC34基因在肿瘤组织中高表达,其表达水平在TNM分期和肿瘤分级之间差异均有统计学意义(t值分别为2.118、3.622,P值分别为0. 035、<0. 001)。CCDC34基因高表达的患者总生存期明显低于CCDC34基因低表达的患者(χ2=21.716,P<0. 05)...

     

  • [1] GOLABI P, FAZEL S, OTGONSUREN M, et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities[J]. Medicine(Baltimore), 2017, 96(9):e5904.
    [2] MEDAVARAM S, ZHANG Y. Emerging therapies in advanced hepatocel ular carcinoma[J]. Exp Hematol Oncol, 2018, 7:17.
    [3] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953.
    [4] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
    [5] GHOURI YA, MIAN I, ROWE JH. Review of hepatocel ular carcinoma:Epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 16:1.
    [6] LUPAS AN, GRUBER M. The structure of alpha-helical coiled coils[J]. Adv Protein Chem, 2005, 70:37-78.
    [7] YIN DT, XU J, LEI M, et al. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma[J]. Oncotarget, 2016, 7(5):5830-5841.
    [8] JIANG GY, ZHANG XP, ZHANG Y, et al. Coiled-coil domaincontaining protein 8 inhibits the invasiveness and migration of nonsmal cel lung cancer cells[J]. Hum Pathol, 2016, 56:64-73.
    [9] TANOUCHI A, TANIUCHI K, FURIHATA M, et al. CCDC88A,a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells[J]. J Exp Clin Cancer Res, 2016, 35(1):190.
    [10] HSIAO KY, LIN YC, GUPTA SK, et al. Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis[J]. Cancer Res, 2017, 77(9):2339-2350.
    [11] KUTSCHE K, GLAUNER E, KNAUF S, et al. Cloning and characterization of the breakpoint regions of a chromosome 11;18 translocation in a patient with hamartoma of the retinal pigment epithelium[J]. Cytogenet Cel Genet, 2000, 91(1-4):141-147.
    [12] ROBINSON MD, MCCARTHY DJ, SMYTH GK. edgeR:A Bioconductor package for differential expression analysis of digital gene expression data[J]. Bioinformatics, 2010, 26(1):139-140.
    [13] DILLIES MA, RAU A, AUBERT J, et al. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis[J]. Brief Bioinform, 2013,14(6):671-683.
    [14] SUBRAMANIAN A, TAMAYO P, MOOTHA VK, et al. Gene set enrichment analysis:A knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci U S A, 2005, 102(43):15545-15550.
    [15] KANEHISA M, FURUMICHI M, TANABE M, et al. KEGG:New perspectives on genomes, pathways, diseases and drugs[J].Nucleic Acids Res, 2017, 45(D1):d353-d361.
    [16] SUBRAMANIAN A, KUEHN H, GOULD J, et al. GSEA-P:A desktop application for Gene Set Enrichment Analysis[J].Bioinformatics, 2007, 23(23):3251-3253.
    [17] MAEYAMA Y, OTSU M, KUBO S, et al. Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region[J]. Int J Oncol, 2011, 39(1):41-49.
    [18] LIU Z, MAI C, YANG H, et al. Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers[J]. J Cell Mol Med, 2014, 18(8):1667-1679.
    [19] GENG W, LIANG W, FAN Y, et al. Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion[J]. Mol Med Rep, 2018, 17(1):465-473.
    [20] HU DD, LI PC, HE YF, et al. Overexpression of coiled-coil domain-containing protein 34(CCDC34)and its correlation with angiogenesis in esophageal squamous cell carcinoma[J]. Med Sci Monit, 2018, 24:698-705.
    [21] STARK GR, TAYLOR WR. Control of the G2/M transition[J].Mol Biotechnol, 2006, 32(3):227-248.
    [22] GONG Y, QIU W, NING X, et al. CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation,apoptosis and migration[J]. Oncotarget, 2015, 6(28):25856-25867.
    [23] PANI B, NUDLER E. Mechanistic insights into transcription coupled DNA repair[J]. DNA Repair(Amst), 2017, 56:42-50.
    [24] MAHAMUD O, SO J, CHUA M, et al. Targeting DNA repair for precision radiotherapy:Balancing the therapeutic ratio[J].Curr Probl Cancer, 2017, 41(4):265-272.
    [25] MURAI J. Targeting DNA repair and replication stress in the treatment of ovarian cancer[J]. Int J Clin Oncol, 2017, 22(4):619-628.
    [26] GENTIEN D, KOSMIDER O, NGUYEN-KHAC F, et al. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages[J]. Leukemia, 2014, 28(6):1355-1357.
  • 加载中
计量
  • 文章访问数:  984
  • HTML全文浏览量:  56
  • PDF下载量:  148
  • 被引次数: 0
出版历程
  • 出版日期:  2020-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回